Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience.

Meaney PM, Kaufman PA, Muffly LS, Click M, Poplack SP, Wells WA, Schwartz GN, di Florio-Alexander RM, Tosteson TD, Li Z, Geimer SD, Fanning MW, Zhou T, Epstein NR, Paulsen KD.

Breast Cancer Res. 2013 Apr 24;15(2):R35. doi: 10.1186/bcr3418.

2.

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.

Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.

J Surg Oncol. 2002 May;80(1):4-11.

PMID:
11967899
3.
4.
5.

Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.

Halim A, Wahba H.

Med Oncol. 2012 Jun;29(2):454-8. doi: 10.1007/s12032-011-9868-1. Epub 2011 Feb 25.

PMID:
21350875
6.

Inflammatory breast cancer after neoadjuvant chemotherapy: can magnetic resonance imaging precisely diagnose the final pathological response?

Chen JH, Mehta RS, Nalcioglu O, Su MY.

Ann Surg Oncol. 2008 Dec;15(12):3609-13. doi: 10.1245/s10434-008-0141-6. Epub 2008 Sep 19. No abstract available.

7.

Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.

Jacobs MA, Ouwerkerk R, Wolff AC, Gabrielson E, Warzecha H, Jeter S, Bluemke DA, Wahl R, Stearns V.

Breast Cancer Res Treat. 2011 Jul;128(1):119-26. doi: 10.1007/s10549-011-1442-1. Epub 2011 Apr 1.

8.

Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.

Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA.

Ann Surg Oncol. 2012 Jan;19(1):253-8. doi: 10.1245/s10434-011-1877-y. Epub 2011 Jul 2.

9.

Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.

Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.

Asian Pac J Cancer Prev. 2012;13(8):4119-23.

10.

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M.

Lancet Oncol. 2013 Jun;14(7):609-18. doi: 10.1016/S1470-2045(13)70166-9. Epub 2013 May 15.

PMID:
23683750
11.

Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.

Bonneterre J, Révillion F, Desauw C, Blot E, Kramar A, Fournier C, Hornez L, Peyrat JP.

Oncol Rep. 2013 Jan;29(1):355-61. doi: 10.3892/or.2012.2090. Epub 2012 Oct 19.

PMID:
23117275
12.

Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.

Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R; ABCSG-14.

J Clin Oncol. 2007 May 20;25(15):2012-8.

13.

Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.

Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T.

Ann Surg Oncol. 2011 Oct;18(11):3160-3. doi: 10.1245/s10434-011-1919-5. Epub 2011 Sep 27.

PMID:
21947594
14.

Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.

Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA.

Cancer J. 2006 May-Jun;12(3):212-21.

PMID:
16803680
15.
16.

Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.

Ju NR, Jeffe DB, Keune J, Aft R.

Breast Cancer Res Treat. 2013 Jan;137(1):195-201. doi: 10.1007/s10549-012-2312-1. Epub 2012 Nov 13.

17.

Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.

Tsunoda-Shimizu H, Hayashi N, Hamaoka T, Kawasaki T, Tsugawa K, Yagata H, Kikuchi M, Suzuki K, Nakamura S.

Breast Cancer. 2008;15(2):133-40. doi: 10.1007/s12282-008-0030-7.

PMID:
18288570
18.

Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.

Cho JH, Park JM, Park HS, Park S, Kim SI, Park BW.

J Surg Oncol. 2013 Dec;108(8):531-6. doi: 10.1002/jso.23439. Epub 2013 Sep 30.

PMID:
24115142
19.

Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.

Demir L, Yigit S, Ellidokuz H, Erten C, Somali I, Kucukzeybek Y, Alacacioglu A, Cokmert S, Can A, Akyol M, Dirican A, Bayoglu V, Sari AA, Tarhan MO.

Clin Exp Metastasis. 2013 Dec;30(8):1047-62. doi: 10.1007/s10585-013-9602-9. Epub 2013 Jul 9.

PMID:
23836289
20.

Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.

Keskin S, Muslumanoglu M, Saip P, Karanlık H, Guveli M, Pehlivan E, Aydoğan F, Eralp Y, Aydıner A, Yavuz E, Ozmen V, Igci A, Topuz E.

Oncology. 2011;81(1):30-8. doi: 10.1159/000330766. Epub 2011 Sep 9.

PMID:
21912195
Items per page

Supplemental Content

Write to the Help Desk